Litigation Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-02-07 |
| Court | District Court, D. Delaware | Date Terminated | 2022-09-12 |
| Cause | 35:1 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | Defendant | Referred To | |
| Parties | SHILPA MEDICARE LIMITED | ||
| Patents | 6,642,245; 6,703,396; 6,838,464; 7,125,879; 7,390,791; 7,803,788; 8,080,551; 8,101,629; 8,754,065; 9,296,769 | ||
| Attorneys | Karen L. Beckman | ||
| Firms | Smith, Katzenstein, & Jenkins LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Gilead Sciences, Inc. v. Apotex, Inc.
Biologic Drugs cited in Gilead Sciences, Inc. v. Apotex, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-02-02 | 189 | Redacted Document | . Nor could it. Claim 1 of asserted U.S. Patent No. 8,754,065 claims “tenofovir alafenamide hemifumarate…to a date by which it will assert any additional patent claims. All of these reasons should be rejected…expiration of two of Gilead’s Orange Book-listed patents. (See D.I. 1 at ¶¶ 192-200.) On February 7, 2020…action against Shilpa for infringement of those two patents, which cover the particular pharmaceutical form…s drug substance with respect to any unasserted patent claims. (Id.) Finally, Shilpa | External link to document |
| 2021-04-01 | 201 | Notice of Service | Trout Regarding Claim Construction of U.S. Patent Nos. 7,390,791; 7,803,788; 8,754,065; and 9,296,769 filed… 12 September 2022 1:20-cv-00189 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2021-05-26 | 236 | Order - -Memorandum and Order | term of U.S. Patent Nos. 7,390,791 (“the ’791 Patent”) and 7,803,788 (“the ’788 Patent”) with agreed-upon…the two prodrug patents asserted in this case, U.S. Patent Nos. 7,390,791 and 7,803,788. …terms of U.S. Patent Nos. 8,754,065 (“the ’065 Patent”) and 9,296,769 (“the ’769 Patent”) are construed…the ’791 patent, which is incorporated by reference in the Hemi patents. (See ’065 patent at 1:16–… diastereomers” (’791 Patent – Claims 1, 4, 7, & 8; ’788 Patent – Claims 1– | External link to document |
| 2020-02-07 | 3 | ANDA Form | 2/2/2022** 8,754,065 8/15/2032 … ATTACHMENT PATENT NUMBER EXPIRATION DATE OF PATENT 7,390,791… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: See Attachment. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: May… SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG | External link to document |
| 2021-10-18 | 359 | Complaint - Amended | identifies the following patents for DESCOVY: U.S. Patent Nos. 6,642,245; 6,703,396; 7,390,791; 7,803,788… identifies the following patents for ODEFSEY: U.S. Patent Nos. 6,642,245; 6,703,396; 6,838,464; 7,125,879…infringed the ’065 patent, the ’769 patent, the ’791 patent, and/or the ’788 patent by submitting its…infringement of the ’065 patent, the ’769 patent, the ’791 patent, and/or the ’788 patent; B) …of the ’065 patent no later than the date on which that patent was issued by the Patent Office and/or | External link to document |
| 2020-02-07 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,390,791 ;7,803,788 ;8,754,065… 12 September 2022 1:20-cv-00189 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
